Overview

Antihyperlipidemic Effects of Oyster Mushrooms

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to evaluate the short-term safety and potential efficacy of oyster mushrooms (Pleurotus ostreatus) for treatment of hyperlipidemia in HIV-infected patients who are taking Kaletra, a protease inhibitor (PI) that is commonly used in highly active antiretroviral therapy (HAART).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Collaborator:
Office of Dietary Supplements (ODS)
Treatments:
Hypolipidemic Agents